• LAST PRICE
    7.5200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.0100/ 2
  • Ask / Lots
    9.7300/ 1
  • Open / Previous Close
    --- / 7.5200
  • Day Range
    ---
  • 52 Week Range
    Low 7.1100
    High 11.4200
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 7.69
TimeVolumePROF
09:32 ET4817.63
10:26 ET4007.719614
10:27 ET2557.6
10:33 ET10007.7652
10:51 ET3007.655
10:58 ET1007.72
11:21 ET5007.6746
11:48 ET10007.6796
11:52 ET1007.64
11:54 ET10007.6058
12:01 ET9147.64
12:37 ET10007.6058
01:00 ET1007.635
01:06 ET18907.595
01:09 ET9707.5
01:24 ET2007.42
02:12 ET1007.4101
02:45 ET10007.5
02:52 ET8897.54
02:59 ET4917.5407
03:06 ET25097.5
03:24 ET3007.56
03:30 ET8227.515
03:35 ET12787.52
03:37 ET4007.52
03:44 ET10007.54
03:57 ET2007.5311
04:00 ET7837.52
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPROF
Profound Medical Corp
260.2M
0.0x
---
As of 2024-11-22

Company Information

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Contact Information

Headquarters
2400 Skymark Ave Unit 6MISSISSAUGA, ON, Canada L4W 5K5
Phone
647-476-1350
Fax
647-476-1350

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$260.2M
Revenue (TTM)
$12.6M
Shares Outstanding
24.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.88
EPS
$-1.87
Book Value
$2.04
P/E Ratio
0.0x
Price/Sales (TTM)
20.7
Price/Cash Flow (TTM)
---
Operating Margin
-368.27%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.